How to Rebuild Reliable U.S. Supply Chains for Medical Products
Calls to bring manufacturing back to America often focus on the location of the final factory. For medical products, that is only part of the picture. A device assembled in the United States may depend on imported electronic components or specialized materials. Our campaign has emphasized domestic manufacturing capacity and concern about concentrated overseas dependencies. The practical question is how to identify fragile links and strengthen them without assuming every imported component is inherently unsafe.
Identify the Medical Products That Matter Most
“Medical products” is not a single manufacturing category. Prescription drugs require processes and controls different from those for sterile disposable supplies. Diagnostic equipment may depend on electronics, precision parts and software, while common protective items use other materials and production lines. A credible supply-chain review should distinguish those product families before proposing solutions.
One starting point is the consequence of an interruption. Would a hospital have an alternative product? Could another qualified manufacturer increase output? Would switching require lengthy validation or additional clinical review? Those are product-specific questions, and their answers may be different even within the same category.
We should also distinguish supply that is geographically concentrated from supply that is genuinely difficult to replace. A risk assessment needs evidence about approved suppliers, production capacity and substitution requirements. Headlines cannot establish urgency.
Map Suppliers Beyond the Final Factory
Consider a hypothetical U.S.-assembled infusion device. Its housing might be made locally while a sensor comes from an overseas supplier and a specialized resin comes from yet another region. If the sensor producer shuts down, the address on the final assembly plant tells us little about the device's ability to reach patients.
A supplier map would follow critical inputs through multiple tiers. It should identify the component specification, actual manufacturing site where known, alternative source, relevant quality evidence and who can confirm a substitute. Some details may be commercially sensitive, so the goal is useful verification rather than public release of every proprietary process.
NIST's 2026 manufacturing traceability work describes a framework for organizing and connecting supply-chain data across different systems. The importance of supplier traceability is practical: decision makers need to distinguish a verified origin from an assumption that a contractor has checked its own suppliers.
A fictional component record could say: “Control sensor; one approved source; manufacturing location confirmed; alternate source identified but not yet qualified.” The origin is known; a usable substitute is not.
Traceability also has limits. Knowing a part's origin does not prove adequate capacity, timely delivery or product quality. Those require separate evidence.
Build Capacity With Smaller U.S. Manufacturers
Expanding domestic production is more involved than placing a purchase order. A company may need skilled technicians, qualified equipment, reliable materials and time to demonstrate that its process meets the relevant product requirements.
Small and medium-sized manufacturers can be part of that effort. The federal Manufacturing Extension Partnership, administered through NIST and its network of centers, provides resources intended to strengthen these manufacturers' operations and competitiveness. Its existence does not mean every applicant receives a grant or that participation certifies a product for medical use.
Workforce preparation matters alongside investment in machinery. Training needs should be specified by the actual manufacturing task: precision assembly, quality documentation, equipment maintenance or another validated skill. Qualification remains a technical decision.
Diversify Where Complete Reshoring Is Unrealistic
Domestic production of every input may be impractical. The resulting choice is broader than “import everything” or “manufacture everything here.”
A resilience plan can combine strategically important U.S. capability with additional qualified sources in different locations. Backups must meet specifications and supply useful quantities. Two suppliers that rely on the same upstream factory do not provide much independence.
Quality cannot be waived. Medical products are subject to requirements that depend on the product and regulator; a proposed replacement material or component may need validation. Public policy should consider these constraints rather than treating a second name on a purchase order as a guaranteed alternative.
Measure Resilience, Not Just the “Made in America” Label
Our national supply chains priorities can be translated into questions that allow progress to be checked over time. Has a second source actually been qualified? Can the buyer trace high-risk components? How long would it take to restore a disrupted production line? How much output can an alternative factory supply without sacrificing standards?
These measures are proposed management tests, not federal performance requirements. Building spare capacity costs money; keeping redundant inventory has storage and shelf-life implications for some medical products. Policymakers and purchasers would need to decide which safeguards justify their costs.
Measure conditions before and after an intervention, not announcements. Domestic assembly matters, but a resilient medical supply chain also needs visible inputs, credible backup capacity and consistent quality.
Our stated concern about manufacturing dependence points toward a measurable implementation challenge. Reliable access to medical products depends on the whole chain, not just a label on the finished package.
